Clinical trials

The purpose of this research study is to see if MK2870 has any benefits at dose levels thought to be acceptable in earlier studies. The researchers want to find out what effects (good and bad) MK2870 has and whether treatment with MK2870 is better than a standard of care treatment of your doctor's choice.

This is a Phase 1 multicenter, open-label study evaluating the safety, tolerability, pharmacokinetics (PK), fetal hemoglobin (HbF) induction and biological activity of FTX-6058 in participants 18-65 years of age, inclusive, with SCD.

To evaluate the efficacy of DA-1229 versus placebo in reducing the progression of aortic valve calcification as measured by cardiac computed tomography (CT) aortic valve calcium score (using the Agatston method and expressed in arbitrary units [AU]) over 2 years (104 weeks) of therapy in subjects with mild to moderate aortic stenosis.

This is a prospective, randomized, controlled, multi-center, clinical trial to demonstrate efficacy of the Nectero EAST System for stabilization of abdominal aortic aneurysms with a maximum diameter of 3.5-5.0 cm.
The trial will enroll and randomize at least 400 subjects, randomized 1:1; to the Treatment arm or Control arm. All subjects will be followed at designated intervals at 30/60days, 6, 12, 18 and 24 months with continued follow-up annually for up to 5 years. The purpose of this trial is to demonstrate the efficacy of the Nectero EAST System by reducing AAA clinical events of small to mid-sized aneurysms compared to current standard of care (surveillance). In addition, the study will evaluate; 1) treatment-related adverse events up to 30-days and 2) the aneurysmal growth rate over time as compared to the untreated Control arm.

A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by open-label extensions, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation.

The purpose of this study is to investigate long-term treatment with a drug called inhaled treprostinil (brand name Tyvaso®) in people with Idiopathic Pulmonary Fibrosis (IPF). 

The purpose of this research study is to see if a drug called inhaled treprostinil will improve lung function in people with Progressive Pulmonary Fibrosis (PPF)

To establish the effectiveness and tolerability of standard of care anti-anginal treatment (beta-blocker and calcium channel blocker medications) in older adults with Stable Ischemic Heart Disease (SIHD) and multiple chronic conditions (MCC).

Determine the impact of bromocriptine on the improvement in LVEF for women presenting with PPCM.

BDTX-1535 was designed to block a growth signal important to some cancers. BDTX-1535 is being tested in this study to see if it can be given safely to people who have tumors that can be dependent on that growth because of changes in a protein called EGFR. These gene changes are called amplifications, mutations or alterations and are found only in the tumors. Your tests have shown that your tumor has an alteration in EGFR. These changes do not exist in normal tissue, so there is an opportunity to block the growth of the cancer cells while allowing signals used by normal cells. This study is being done to find answers to the following:
•    How often and how much of the study drug should be given to cancer patients?

•    What are the side effects of the study drug?
•    How long after dosing does the study drug remain in your body with and without food?
•    How does the study drug affect biomarkers? Biomarkers are substances in your body that can be measured to help track the status of your disease, such as DNA, RNA, and proteins. These substances in blood will be tested to learn if the study drug changes the way the cancer behaves.
•    Can the study drug help patients with your type of cancer?